134 related articles for article (PubMed ID: 26685653)
41. Targeting bone metastases in prostate cancer: improving clinical outcome.
Body JJ; Casimiro S; Costa L
Nat Rev Urol; 2015 Jun; 12(6):340-56. PubMed ID: 26119830
[TBL] [Abstract][Full Text] [Related]
42. Current therapeutic options targeting bone metastasis in metastatic castration resistant prostate cancer.
Fragkoulis C; Gkialas I; Papadopoulos G; Ntoumas K
J BUON; 2016; 21(4):787-791. PubMed ID: 27685897
[TBL] [Abstract][Full Text] [Related]
43. Use of Radium-223 Dichloride in Patients With Osteonecrosis of the Jaw Induced by Zoledronic Acid: Report of 2 Cases.
Dionisi V; Bellarosa C; Cardano R; Rizzini EL; Ghedini P; Morganti AG; Fanti S; Monari F
Clin Genitourin Cancer; 2019 Jun; 17(3):e612-e617. PubMed ID: 30956096
[No Abstract] [Full Text] [Related]
44. Use of radium-223 in men with metastatic castration-resistant prostate cancer.
Parker C
Clin Adv Hematol Oncol; 2015 Nov; 13(11):723-5. PubMed ID: 27058695
[No Abstract] [Full Text] [Related]
45. Radium Ra 223 dichloride in castration-resistant prostate cancer.
Joung JY; Ha YS; Kim IY
Drugs Today (Barc); 2013 Aug; 49(8):483-90. PubMed ID: 23977665
[TBL] [Abstract][Full Text] [Related]
46. When to initiate treatment with radium-223 in patients with metastatic castration-resistant prostate cancer.
Shore ND
Clin Adv Hematol Oncol; 2016 Jan; 14(1):26-9. PubMed ID: 27057663
[No Abstract] [Full Text] [Related]
47. Treatment landscape of metastatic prostate cancer: the role of radium-223.
Dermine A; Machiels JP
Acta Clin Belg; 2017 Feb; 72(1):19-23. PubMed ID: 27377415
[TBL] [Abstract][Full Text] [Related]
48. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.
Saad F; Carles J; Gillessen S; Heidenreich A; Heinrich D; Gratt J; Lévy J; Miller K; Nilsson S; Petrenciuc O; Tucci M; Wirth M; Federhofer J; O'Sullivan JM;
Lancet Oncol; 2016 Sep; 17(9):1306-16. PubMed ID: 27473888
[TBL] [Abstract][Full Text] [Related]
49. Re: Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.
Taneja SS
J Urol; 2015 Mar; 193(3):847-8. PubMed ID: 25765385
[No Abstract] [Full Text] [Related]
50. Radium Ra 223 dichloride injection: U.S. Food and Drug Administration drug approval summary.
Kluetz PG; Pierce W; Maher VE; Zhang H; Tang S; Song P; Liu Q; Haber MT; Leutzinger EE; Al-Hakim A; Chen W; Palmby T; Alebachew E; Sridhara R; Ibrahim A; Justice R; Pazdur R
Clin Cancer Res; 2014 Jan; 20(1):9-14. PubMed ID: 24190979
[TBL] [Abstract][Full Text] [Related]
51. [Castration resistant prostate cancer 2015].
Merseburger AS; Böker A; Kuczyk MA; von Klot CA
Aktuelle Urol; 2015 Jan; 46(1):59-65. PubMed ID: 25658232
[TBL] [Abstract][Full Text] [Related]
52. Nursing management of patients with castration-resistant prostate cancer undergoing radium-223 dichloride treatment.
Delacruz A; Arauz G; Curley T; Lindo A; Jensen T
Clin J Oncol Nurs; 2015 Apr; 19(2):E31-5. PubMed ID: 25840395
[TBL] [Abstract][Full Text] [Related]
53. A Retrospective Analysis of the First 41 mCRPC Patients with Bone Pain Treated with Radium-223 at the National Institute of Oncology in Hungary.
Küronya Z; Sinkovics I; Ágoston P; Bíró K; Bodrogi I; Böde I; Dank M; Gyergyay F; Vajdics T; Kolonics Z; Nagyiványi K; Rúzsa Á; Géczi L
Pathol Oncol Res; 2017 Oct; 23(4):777-783. PubMed ID: 28074331
[TBL] [Abstract][Full Text] [Related]
54. Radium 223 dichloride for prostate cancer treatment.
Deshayes E; Roumiguie M; Thibault C; Beuzeboc P; Cachin F; Hennequin C; Huglo D; Rozet F; Kassab-Chahmi D; Rebillard X; Houédé N
Drug Des Devel Ther; 2017; 11():2643-2651. PubMed ID: 28919714
[TBL] [Abstract][Full Text] [Related]
55. Prostate cancer bone metastases: not so systemic after all.
Logothetis CJ
Lancet Oncol; 2014 Jun; 15(7):675-6. PubMed ID: 24836275
[No Abstract] [Full Text] [Related]
56. [Bone-specific therapy with radium-223 dichloride : Castration-resistant prostate cancer with symptomatic bone metastases].
Tauber R; Gschwend J; Scheidhauer K; Eiber M; Krönke M
Urologe A; 2017 Jan; 56(1):24-31. PubMed ID: 28058455
[TBL] [Abstract][Full Text] [Related]
57. Urological cancer: α-emitting radium-223-additional choices, more unknowns.
Higano C
Nat Rev Clin Oncol; 2013 Nov; 10(11):612-3. PubMed ID: 24019065
[No Abstract] [Full Text] [Related]
58. Acute Promyelocytic Leukemia After Treatment of Metastatic Castration-Resistant Prostate Cancer With Radium-223.
Odo U; Vasudevamurthy AK; Sartor O
Clin Genitourin Cancer; 2017 Jun; 15(3):e501-e502. PubMed ID: 28111175
[No Abstract] [Full Text] [Related]
59. Editorial Comment to Bone-modifying agents are protective for symptomatic skeletal events in radium-223 treatment.
Yuasa T
Int J Urol; 2023 Nov; 30(11):1034-1035. PubMed ID: 37615335
[No Abstract] [Full Text] [Related]
60. Radium-223 chloride: Extending life in prostate cancer patients by treating bone metastases.
Wissing MD; van Leeuwen FW; van der Pluijm G; Gelderblom H
Clin Cancer Res; 2013 Nov; 19(21):5822-7. PubMed ID: 24052017
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
